{
    "clinical_study": {
        "@rank": "4854", 
        "arm_group": {
            "arm_group_label": "Lenti-D Drug Product", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This trial will assess the efficacy and safety of autologous CD34+ hematopoietic stem cells,\n      transduced ex-vivo with Lenti-D lentiviral vector, for the treatment of childhood cerebral\n      adrenoleukodystrophy (CCALD). A subject's blood stem cells will be collected and modified\n      using the Lenti-D lentiviral vector to add a functional copy of the human ABCD1 (ATP-binding\n      cassette, sub-family D, member 1) complementary DNA (cDNA). After modification with the\n      Lenti-D lentiviral vector, the cells will be transplanted back into the subject following\n      myeloablative conditioning."
        }, 
        "brief_title": "A Phase 2/3 Study of the Efficacy and Safety of Hematopoietic Stem Cells Transduced With Lenti-D Lentiviral Vector for the Treatment of Childhood Cerebral Adrenoleukodystrophy (CCALD)", 
        "condition": [
            "Childhood Cerebral Adrenoleukodystrophy", 
            "(X-linked Adrenoleukodystrophy Cerebral Childhood)"
        ], 
        "condition_browse": {
            "mesh_term": "Adrenoleukodystrophy"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Informed consent is obtained from a competent custodial parent or guardian with legal\n             capacity to execute a local Institutional Review Board (IRB)/Independent Ethics\n             Committee (IEC) approved consent. (Informed assent will be sought from capable\n             subjects, in accordance with the directive of the IRB/IEC and with local\n             requirements).\n\n          -  Boys aged 17 years and younger, at the time of parental/guardian consent and, where\n             appropriate, subject assent.\n\n          -  Active cerebral ALD as defined by: Elevated VLCFA levels, and active central nervous\n             system (CNS) disease established by central radiographic review of brain MRI\n             demonstrating:\n\n             i. Loes score between 0.5 and 9 (inclusive) on the 34-point scale, and ii. Gadolinium\n             enhancement of demyelinating lesions on MRI.\n\n          -  NFS \u2264 1.\n\n        Exclusion Criteria:\n\n          -  Receipt of an allogeneic transplant or gene therapy.\n\n          -  Availability of a willing 10/10 human leukocyte antigen (HLA)-matched sibling donor.\n\n          -  Use of statins, Lorenzo's Oil, or dietary regimens used to lower VLCFA levels. Note:\n             subjects must discontinue use of these medications at time of consent.\n\n          -  Receipt of an investigational study drug or procedure within 3 months before Day -60\n             that might confound study outcomes.\n\n          -  Any conditions that make it impossible to perform MRI studies (including allergies to\n             anesthetics or contrast agents).\n\n          -  Hematological compromise as evidenced by:\n\n             i. Peripheral blood absolute neutrophil count (ANC) < 1500 cells/mm^3 or, ii.\n             Platelet count < 100,000 cells/mm^3 or, iii. Hemoglobin < 10 g/dL or, iv. Uncorrected\n             bleeding disorder.\n\n          -  Hepatic compromise as evidenced by:\n\n             i. Aspartate transaminase (AST) value > 2.5 \u00d7 the upper limit of normal (ULN) or, ii.\n             Alanine transaminase (ALT) value > 2.5 \u00d7 ULN or, iii. Total bilirubin value > 3.0\n             mg/dL, except if there is a diagnosis of Gilbert's Syndrome and the subject is\n             otherwise stable.\n\n          -  Renal compromise as evidenced by abnormal renal function (creatinine clearance < 50\n             mL/min).\n\n          -  Cardiac compromise as evidenced by left ventricular ejection fraction < 40%.\n\n          -  Immediate family member with a known or suspected Familial Cancer Syndrome.\n\n          -  Clinically significant active bacterial, viral, fungal, or parasitic infection.\n\n          -  Positive for presence of human immunodeficiency virus type 1 or 2 (HIV 1, HIV 2),\n             hepatitis B, hepatitis C, or human T lymphotrophic virus 1 (HTLV 1).\n\n          -  Any clinically significant cardiovascular or pulmonary, or other disease or condition\n             that would be contraindicated for any of the other study procedures."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "17 Years", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "15", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 22, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01896102", 
            "org_study_id": "ALD-102"
        }, 
        "intervention": [
            {
                "arm_group_label": "Lenti-D Drug Product", 
                "description": "Autologous CD34+ hematopoietic stem cells (HSCs) transduced with the lentiviral vector Lenti-D encoding the human ATP-binding cassette, sub-family D, member 1 (ABCD1) cDNA suspended in CryoStor\u00ae CS5 (BioLife\u00ae Solutions) cryopreservative solution containing 5% dimethyl sulfoxide (DMSO).", 
                "intervention_name": "Lenti-D Drug Product", 
                "intervention_type": "Genetic"
            }, 
            {
                "arm_group_label": "Lenti-D Drug Product", 
                "intervention_name": "Busulfan", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Lenti-D Drug Product", 
                "intervention_name": "Cyclophosphamide", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Lenti-D Drug Product", 
                "intervention_name": "Filgrastim", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Busulfan", 
                "Cyclophosphamide", 
                "Lenograstim"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Adrenoleukodystrophy", 
            "X-linked adrenoleukodystrophy", 
            "Gene therapy", 
            "Hematopoietic stem cell"
        ], 
        "lastchanged_date": "April 4, 2014", 
        "location": {
            "contact": {
                "email": "Colleen.Dansereau@childrens.harvard.edu", 
                "last_name": "Colleen Dansereau", 
                "phone": "617-919-7008"
            }, 
            "facility": {
                "address": {
                    "city": "Boston", 
                    "country": "United States", 
                    "state": "Massachusetts", 
                    "zip": "02115"
                }, 
                "name": "Boston Children's Hospital/Massachusetts General Hospital"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 2/3 Study of the Efficacy and Safety of Hematopoietic Stem Cells Transduced With Lenti-D Lentiviral Vector for the Treatment of Childhood Cerebral Adrenoleukodystrophy (CCALD)", 
        "overall_contact": {
            "email": "clinicaltrials@bluebirdbio.com", 
            "last_name": "Tara O'Meara", 
            "phone": "617-797-2555"
        }, 
        "overall_official": [
            {
                "affiliation": "bluebird bio, Inc.", 
                "last_name": "Asif Paker, M.D.", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "Children's Hospital Boston", 
                "last_name": "David Williams, M.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Children's Hospital Boston", 
                "last_name": "Christine Duncan, M.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Massachusetts General Hospital", 
                "last_name": "Florian Eichler, M.D.", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "August 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Assessment of the proportion of subjects who have no Major Functional Disabilities (MFDs) as determined by key measures in the Neurological Function Score (NFS).", 
            "safety_issue": "No", 
            "time_frame": "24 months (\u00b12 months) post-transplant"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01896102"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change from Baseline in Loes score as measured by brain MRI.", 
                "safety_issue": "No", 
                "time_frame": "24 mon (\u00b12 months) post-transplant"
            }, 
            {
                "measure": "Change from Baseline in NFS.", 
                "safety_issue": "No", 
                "time_frame": "24 mon (\u00b1 2 months) post-transplant"
            }, 
            {
                "description": "Proportion of subjects who demonstrate resolution of gadolinium positivity on MRI (i.e., who are gadolinium negative) at 24 months (\u00b1 2 months) post-transplant.", 
                "measure": "Resolution of gadolinium positivity on MRI", 
                "safety_issue": "No", 
                "time_frame": "24 mon (\u00b1 2 months) post-transplant"
            }
        ], 
        "source": "bluebird bio", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "bluebird bio", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}